CN Patent

CN116120284A — 一种吲哚衍生物及其应用

Assigned to Wuhan Zhongcheng Kangjian Biomedical Technology Co ltd · Expires 2023-05-16 · 3y expired

What this patent protects

本发明公开了一种吲哚衍生物及其应用，所述吲哚衍生物能有效抑制VEGF和FGF的高表达，特别是显著抑制VEGFR2、FGFR1和FGFR4激酶活性，具有良好成药前景；可应用于制备抗血管生成抑制剂，尤其是应用于制备抗血管生成相关疾病的药物组合物，特别是应用于制备抗VEGFR和/或FGFR蛋白活性异常相关肿瘤的药物；尤其是应用于制备抗神经胶质瘤和恶性肿瘤的药物。

USPTO Abstract

本发明公开了一种吲哚衍生物及其应用，所述吲哚衍生物能有效抑制VEGF和FGF的高表达，特别是显著抑制VEGFR2、FGFR1和FGFR4激酶活性，具有良好成药前景；可应用于制备抗血管生成抑制剂，尤其是应用于制备抗血管生成相关疾病的药物组合物，特别是应用于制备抗VEGFR和/或FGFR蛋白活性异常相关肿瘤的药物；尤其是应用于制备抗神经胶质瘤和恶性肿瘤的药物。

Drugs covered by this patent

Patent Metadata

Patent number
CN116120284A
Jurisdiction
CN
Classification
—
Expires
2023-05-16
Drug substance claim
No
Drug product claim
No
Assignee
Wuhan Zhongcheng Kangjian Biomedical Technology Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.